Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
36 hedge funds and large institutions have $20.7M invested in Merrimack Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 4 closing their positions.
47% more capital invested
Capital invested by funds: $14.1M → $20.7M (+$6.65M)
3% less funds holding
Funds holding: 37 → 36 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$90.2K |
| 2 |
NM
Newtyn Management
New York
|
+$90.2K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$25.8K |
| 4 |
WR
Watson Rebecca
|
+$10.5K |
| 5 |
BlackRock
New York
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sepio Capital
Salt Lake City,
Utah
|
-$488K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$193K |
| 3 |
LA
LVW Advisors
Pittsford,
New York
|
-$149K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$143K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$129K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BWP
26
Baldwin Wealth Partners
Marion,
Massachusetts
| $2K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $1K | -$8.03K | -2,353 | -92% |
|
28
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$2.17K | -635 | -62% |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$229 | -67 | -17% |
|
|
SSB
30
Sandy Spring Bank
Olney,
Maryland
| $1K | – | – | – |
|
|
TFGT
31
TS Financial Group (TSFG)
Lake Forest,
Illinois
| $1K | – | – | – |
|
32
BNP Paribas Financial Markets
Paris,
France
| $17 | – | – | – |
|
|
LA
33
LVW Advisors
Pittsford,
New York
| – | -$149K | -69,293 | Closed |
|
34
Victory Capital Management
San Antonio,
Texas
| – | -$10K | -4,352 | Closed |
|
35
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -1,103 | Closed |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| – | -$2K | -773 | Closed |
|
37
Fidelity Investments
Boston,
Massachusetts
| – | -$27 | -8 | -89% |
|
MACK Hedge Fund Activity: Q2 2020 in Review
36 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2020, worth a combined $20.7M — up 47% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MACK and 3 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 5 added.
The largest buyer was Western Standard LLC, adding an estimated $90.2K. The largest seller was Sepio Capital, cutting an estimated $488K.
- 36 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2020, down from 37 in Q1 2020.
- Funds reported $20.7M of Merrimack Pharmaceuticals, Inc. stock for Q2 2020, up 47% quarter-over-quarter.
- 3 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2020 and 4 closed out, a net change of -1 holder.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2020 was Western Standard LLC, an estimated $90.2K added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2020 was Sepio Capital, an estimated $488K sold.
Based on aggregated 13F filings for Q2 2020.